Core Viewpoint - The recent announcement by Vaili Zhibo has not garnered significant market attention despite the potential of its core product reaching key R&D milestones, which typically attracts investor interest in the Hong Kong stock market for unprofitable 18A companies [3][4]. Market Reaction - Following the announcement, Vaili Zhibo's stock price rose by 3.15% and 1.44% on January 15 and 16, respectively, but subsequently experienced a "three consecutive declines" trend, influenced by the overall pullback in the Hong Kong medical sector and the upcoming cornerstone lock-up expiration [3][4]. - The Hang Seng Healthcare Index reached a peak of 4326.18 points on January 15 before entering a "four consecutive down" trend, indicating a market correction after a period of gains [4]. Trading Volume and Technical Analysis - Vaili Zhibo experienced a "seven consecutive up" trend from December 30 to January 8, coinciding with the company's participation in the JPM conference, but this rally lacked substantial trading volume support, indicating a potential "false breakout" in technical terms [6][8]. - The daily trading volume peaked at 224.58 million shares at the start of the rally but subsequently declined, suggesting a lack of market support and leading to a downward price trend [6]. Cornerstone Lock-up Expiration - Vaili Zhibo's cornerstone investors, who collectively subscribed for $69 million (approximately 542 million HKD) during the IPO, will face a lock-up expiration on January 25, 2025, which could lead to profit-taking and market pressure [8][10]. - As of January 21, the stock price was 51.25 HKD, indicating that cornerstone investors have an approximate 50% unrealized gain, providing them with a favorable exit opportunity [8]. Future Market Dynamics - The upcoming inclusion of Vaili Zhibo in the Hong Kong Stock Connect program in March 2025, with an average market capitalization of 9.462 billion HKD, positions it as a potential target for new capital inflows [10][12]. - The behavior of cornerstone investors during the lock-up expiration will serve as a critical indicator for market sentiment and could influence the stock's performance in the context of new capital entering the market [10][14]. Company Fundamentals - Vaili Zhibo's innovative strategy focuses on T cell connectors, tumor immunology 2.0, and antibody-drug conjugates, with its core product LBL-024 being a significant asset in its pipeline [13][14]. - LBL-024 has received fast track designation from the FDA for treating neuroendocrine cancer, highlighting its potential and the recognition from regulatory bodies [13].
板块跳水叠加基石解禁，维立志博-B何以吸引即将到来的北水资金？